| Methods |
RCT
Assessor blinded
1993‐1995 |
| Participants |
Number: 281 patients (324 episodes)
Age: med52, mean 50.1, SD 16.6 |
| Interventions |
cefepime 2grx3
versus
ceftazidime 2grx3
Additional glycopeptides administered to <1% of patients (in both arms). |
| Outcomes |
Overall and infection‐related mortality ‐ at 30 days after end of treatment
Clinical and microbiological failure
Superinfection
Drug modifications
Adverse events |
| Notes |
MC Europe |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
No description |
| Allocation concealment? |
Unclear risk |
No description |
| Blinding?
All outcomes |
High risk |
Only outcome assessor blinded |
| Incomplete outcome data addressed?
All‐cause mortality |
Low risk |
|
| Incomplete outcome data addressed?
Treatment failure |
High risk |
Number of dropouts (4%) known per study group |
| Free of other bias? |
Low risk |
|
